Balance Sheet

Accounts Payables Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Leases Current Taxes Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Legend Biotech (LEGN) Finished Goods (2024 - 2025)

Legend Biotech filings provide 2 years of Finished Goods readings, the most recent being $2.8 million for Q1 2025.

On a quarterly basis, Finished Goods changed N/A to $2.8 million in Q1 2025 year-over-year; TTM through Mar 2025 was $2.8 million, a N/A change, with the full-year FY2024 number at $2.0 million, changed N/A from a year prior.
Finished Goods hit $2.8 million in Q1 2025 for Legend Biotech, up from $2.0 million in the prior quarter.
In the past five years, Finished Goods ranged from a high of $2.8 million in Q1 2025 to a low of $2.0 million in Q4 2024.